How do serotonergic psychedelics treat depression:The potential role of neuroplasticity  

作　　者：Hewa Artin Sidney Zisook Dhakshin Ramanathan 

机构地区：[1]Department of Psychiatry,UC San Diego,La Jolla,CA 92093,United States [2]Department of Psychiatry,UC San Diego,San Diego,CA 92093,United States [3]Department of Psychiatry,VA San Diego Healthcare System,San Diego,CA 92161,United States

出　　处：《World Journal of Psychiatry》2021年第6期201-214,共14页世界精神病学杂志

摘　　要：Depression is a common mental disorder and one of the leading causes of disability around the world.Monoaminergic antidepressants often take weeks to months to work and are not effective for all patients.This has led to a search for a better understanding of the pathogenesis of depression as well as to the development of novel antidepressants.One such novel antidepressant is ketamine,which has demonstrated both clinically promising results and contributed to new explanatory models of depression,including the potential role of neuroplasticity in depression.Early clinical trials are now showing promising results of serotonergic psychedelics for depression;however,their mechanism of action remains poorly understood.This paper seeks to review the effect of depression,classic antidepressants,ketamine,and serotonergic psychedelics on markers of neuroplasticity at a cellular,molecular,electrophysiological,functional,structural,and psychological level to explore the potential role that neuroplasticity plays in the treatment response of serotonergic psychedelics.

关 键 词：Serotonergic psychedelics Psychedelics DEPRESSION Antidepressants NEUROPLASTICITY KETAMINE HALLUCINOGENS 

分 类 号：R749.4[医药卫生—神经病学与精神病学]